Medical Research
Odylia Therapeutics Inc
ATLANTA, GA
Total revenue
$482K
Total expenses
$699K
Net assets
$688K
Grants received
$2.9M
20 grants
EIN
822120760
Tax year
2024
Mission
Odlyia utilizes a unique, non-profit model to accelerate the development of gene therapies for people with rare disease, changing the way treatments are brought from the lab to the clinic.
Financials
FY 2024
Revenue
Expenses
People
8 listed
ASHLEY WINSLOW
CEO/CSO
$218K
40 hrs/wk
SCOTT DORFMAN
BOARD CHAIR
—
3 hrs/wk
ELIZABETH ATTIAS
BOARD MEMBER
—
1 hrs/wk
KHANDAN BARADARAN
BOARD MEMBER
—
1 hrs/wk
BRIAN FENTON
BOARD MEMBER
—
1 hrs/wk
MATTHEW PLETCHER
BOARD MEMBER
—
1 hrs/wk
GREG ROBINSON
BOARD MEMBER
—
1 hrs/wk
JENNIFER KLEIN
MGR. OF OPERATIONS & PROG. MGMT.
$116K
40 hrs/wk
Grants received
Showing 20 of 20
Funded by
$2.9M from 10 funders · 20 grants · 2020–2024
$1.5M · 2 grants · 2023–2024
$602K · 4 grants · 2020–2024
$500K · 1 grant · 2021
$68K · 2 grants · 2022–2023
$53K · 3 grants · 2022–2024
$50K · 2 grants · 2021–2022
$50K · 1 grant · 2021
$50K · 2 grants · 2022–2023